NF2 and meningioma: Among 37 NF2 patients with meningiomas, germline NF2 alterations were identified in 18 patients (48.6%), including truncating mutations (9, 24.3%), large deletions (2, 5.4%), splice-site mutations (6, 16.2%), and missense mutations (1, 2.7%) (Table 1).